- Home
- GLPG vs SPRY Comparison
GLPG vs SPRY Comparison
Compare GLPG & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- SPRY
- Stock Information
- Founded
- GLPG 1999
- SPRY 2015
- Country
- GLPG Belgium
- SPRY United States
- Employees
- GLPG N/A
- SPRY N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- GLPG Health Care
- SPRY Health Care
- Exchange
- GLPG Nasdaq
- SPRY Nasdaq
- Market Cap
- GLPG 2.1B
- SPRY 1.8B
- IPO Year
- GLPG 2005
- SPRY N/A
- Fundamental
- Price
- GLPG $34.50
- SPRY $11.08
- Analyst Decision
- GLPG Sell
- SPRY Strong Buy
- Analyst Count
- GLPG 3
- SPRY 5
- Target Price
- GLPG $26.00
- SPRY $31.00
- AVG Volume (30 Days)
- GLPG 203.5K
- SPRY 2.8M
- Earning Date
- GLPG 10-29-2025
- SPRY 11-12-2025
- Dividend Yield
- GLPG N/A
- SPRY N/A
- EPS Growth
- GLPG N/A
- SPRY N/A
- EPS
- GLPG N/A
- SPRY N/A
- Revenue
- GLPG $323,674,692.00
- SPRY $112,339,000.00
- Revenue This Year
- GLPG $1.77
- SPRY N/A
- Revenue Next Year
- GLPG $0.44
- SPRY $188.92
- P/E Ratio
- GLPG N/A
- SPRY N/A
- Revenue Growth
- GLPG 5.43
- SPRY 22367.80
- 52 Week Low
- GLPG $22.36
- SPRY $9.34
- 52 Week High
- GLPG $37.78
- SPRY $18.90
- Technical
- Relative Strength Index (RSI)
- GLPG 54.01
- SPRY 54.91
- Support Level
- GLPG $32.37
- SPRY $10.00
- Resistance Level
- GLPG $37.78
- SPRY $11.03
- Average True Range (ATR)
- GLPG 0.77
- SPRY 0.53
- MACD
- GLPG 0.00
- SPRY 0.32
- Stochastic Oscillator
- GLPG 39.93
- SPRY 98.36
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.